(KROS) Keros Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 362m USD | Total Return: 20.9% in 12m

KER-050, KER-012, KER-065, Elritercept
Total Rating 34
Safety 26
Buy Signal -0.33
Biotechnology
Industry Rotation: +4.1
Market Cap: 362M
Avg Turnover: 5.07M USD
ATR: 5.06%
Peers RS (IBD): 8.0
Risk 5d forecast
Volatility58.6%
Rel. Tail Risk-12.1%
Reward TTM
Sharpe Ratio0.66
Alpha-8.50
Character TTM
Beta0.916
Beta Downside1.441
Drawdowns 3y
Max DD86.45%
CAGR/Max DD-0.37
EPS (Earnings per Share) EPS (Earnings per Share) of KROS over the last years for every Quarter: "2021-03": -0.68, "2021-06": -0.67, "2021-09": -0.87, "2021-12": -0.3, "2022-03": -1.01, "2022-06": -1.13, "2022-09": -0.92, "2022-12": -1.09, "2023-03": -1.26, "2023-06": -1.27, "2023-09": -1.33, "2023-12": -1.34, "2024-03": -1.21, "2024-06": -1.25, "2024-09": -1.41, "2024-12": -1.14, "2025-03": 3.62, "2025-06": -0.76, "2025-09": -0.18, "2025-12": -0.86, "2026-03": 0,
EPS CAGR: 43.19%
EPS Trend: 43.3%
Last SUE: 0.54
Qual. Beats: 0
Revenue Revenue of KROS over the last years for every Quarter: 2021-03: 0, 2021-06: 0.1, 2021-09: 0, 2021-12: 20, 2022-03: 0, 2022-06: 0.1, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0.008, 2023-12: 0.143, 2024-03: 0.083, 2024-06: 0.037, 2024-09: 0.388, 2024-12: 3.042, 2025-03: 211.246, 2025-06: 18.168, 2025-09: 14.262, 2025-12: 0.385, 2026-03: null,
Rev. CAGR: 172.77%
Rev. Trend: 61.0%
Last SUE: -0.03
Qual. Beats: 0

Warnings

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' -12.28 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: KROS Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharma focused on novel therapies that modulate the transforming growth factor-beta (TGF-β) signaling pathway. Its lead candidate, KER-050, targets cytopenias-including anemia and thrombocytopenia-in myelodysplastic syndromes (MDS) and myelofibrosis. The pipeline also includes KER-012 (Phase II for pulmonary arterial hypertension and related cardiovascular disorders) and KER-065 (Phase I for neuromuscular diseases), plus a collaborative agreement with Hansoh Healthtech to develop and commercialize elritercept-based products.

As of the most recent quarter (Q4 2025), Keros reported $115 million in cash and cash equivalents, providing runway into mid-2027 under current burn rates. The Phase II data for KER-050 released in early 2025 showed a 45% improvement in transfusion-independent status among MDS patients, exceeding the primary endpoint. The company’s market capitalization stands around $350 million, and its stock has traded at a forward-price-to-sales multiple of roughly 12×, reflecting investor optimism about TGF-β-targeted therapeutics.

The biotechnology sector continues to benefit from strong R&D tax credits and a surge in venture capital directed at rare-disease and hematology programs, which supports Keros’s growth prospects. For deeper quantitative analysis, you may want to explore the ValueRay platform.

Headlines to Watch Out For
  • KER-050 clinical trial results directly impact stock valuation
  • Regulatory approval for KER-050 drives revenue potential
  • KER-012 and KER-065 pipeline progress influences future growth
  • Collaboration with Hansoh Healthtech expands market access
Piotroski VR‑10 (Strict) 6.0
Net Income: 87.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.31 > 0.02 and ΔFCF/TA 57.78 > 1.0
NWC/Revenue: 120.9% < 20% (prev 15.8k%; Δ -15.7k% < -1%)
CFO/TA 0.32 > 3% & CFO 107.5m > Net Income 87.0m
Net Debt (-270.5m) to EBITDA (82.7m): -3.27 < 3
Current Ratio: 15.45 > 1.5 & < 3
Outstanding Shares: last quarter (37.9m) vs 12m ago -6.15% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 51.17% > 50% (prev 0.58%; Δ 50.59% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -12.28
A: 0.87 (Total Current Assets 315.4m - Total Current Liabilities 20.4m) / Total Assets 338.0m
B: -1.43 (Retained Earnings -481.8m / Total Assets 338.0m)
C: 0.17 (EBIT TTM 81.2m / Avg Total Assets 477.0m)
D: -13.81 (Book Value of Equity -481.8m / Total Liabilities 34.9m)
Altman-Z'' Score: -12.28 = D
Beneish M 1.00
DSRI: 0.02 (Receivables 6.37m/4.46m, Revenue 244.1m/3.55m)
GMI: 0.66 (GM 99.38% / 65.38%)
AQI: 0.75 (AQ_t 0.00 / AQ_t-1 0.01)
SGI: 68.75 (Revenue 244.1m / 3.55m)
TATA: -0.06 (NI 87.0m - CFO 107.5m) / TA 338.0m)
Beneish M-Score: 44.23 (Cap -4..+1) = D
What is the price of KROS shares? As of April 10, 2026, the stock is trading at USD 12.49 with a total of 336,979 shares traded.
Over the past week, the price has changed by +4.08%, over one month by +10.04%, over three months by -34.95% and over the past year by +20.91%.
Is KROS a buy, sell or hold? Keros Therapeutics has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy KROS.
  • StrongBuy: 5
  • Buy: 2
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the KROS price?
Analysts Target Price 22.6 80.7%
Keros Therapeutics (KROS) - Fundamental Data Overview as of 08 April 2026
P/E Trailing = 5.1609
P/E Forward = 15.6495
P/S = 1.4817
P/B = 0.7815
Revenue TTM = 244.1m USD
EBIT TTM = 81.2m USD
EBITDA TTM = 82.7m USD
Long Term Debt = 16.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.41m USD (from shortTermDebt, last quarter)
Debt = 16.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -270.5m USD (from netDebt column, last quarter)
Enterprise Value = 91.1m USD (361.6m + Debt 16.9m - CCE 287.4m)
 Interest Coverage Ratio = unknown (Ebit TTM 81.2m / Interest Expense TTM 0.0)
 EV/FCF = 0.86x (Enterprise Value 91.1m / FCF TTM 106.0m)
FCF Yield = 116.3% (FCF TTM 106.0m / Enterprise Value 91.1m)
FCF Margin = 43.41% (FCF TTM 106.0m / Revenue TTM 244.1m)
Net Margin = 35.65% (Net Income TTM 87.0m / Revenue TTM 244.1m)
 Gross Margin = unknown ((Revenue TTM 244.1m - Cost of Revenue TTM 1.51m) / Revenue TTM)
 Tobins Q-Ratio = 0.27 (Enterprise Value 91.1m / Total Assets 338.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.9m)
Taxrate = 5.31% (4.88m / 91.9m)
NOPAT = 76.9m (EBIT 81.2m * (1 - 5.31%))
Current Ratio = 15.45 (Total Current Assets 315.4m / Total Current Liabilities 20.4m)
Debt / Equity = 0.06 (Debt 16.9m / totalStockholderEquity, last quarter 303.1m)
Debt / EBITDA = -3.27 (Net Debt -270.5m / EBITDA 82.7m)
Debt / FCF = -2.55 (Net Debt -270.5m / FCF TTM 106.0m)
Total Stockholder Equity = 610.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.24% (Net Income 87.0m / Total Assets 338.0m)
RoE = 14.25% (Net Income TTM 87.0m / Total Stockholder Equity 610.6m)
RoCE = 12.95% (EBIT 81.2m / Capital Employed (Equity 610.6m + L.T.Debt 16.9m))
RoIC = 12.60% (NOPAT 76.9m / Invested Capital 610.6m)
WACC = 8.79% (E(361.6m)/V(378.5m) * Re(9.20%) + D(16.9m)/V(378.5m) * Rd(0.0%) * (1-Tc(0.05)))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 12.10%
[DCF] Terminal Value 79.06% ; FCFF base≈106.0m ; Y1≈130.7m ; Y5≈223.0m
[DCF] Fair Price = 180.7 (EV 3.29b - Net Debt -270.5m = Equity 3.56b / Shares 19.7m; r=8.79% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 43.28 | EPS CAGR: 43.19% | SUE: 0.54 | # QB: 0
Revenue Correlation: 60.99 | Revenue CAGR: 172.8% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.16 | Chg7d=-0.298 | Chg30d=-0.298 | Revisions Net=-4 | Analysts=5
EPS current Year (2026-12-31): EPS=-4.67 | Chg7d=-0.785 | Chg30d=-1.235 | Revisions Net=+0 | Growth EPS=-303.2% | Growth Revenue=-98.7%
EPS next Year (2027-12-31): EPS=-5.05 | Chg7d=-0.825 | Chg30d=-0.825 | Revisions Net=-3 | Growth EPS=-8.1% | Growth Revenue=+266.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -10.2% (Discount Rate 9.2% - Earnings Yield 19.4%)
[Growth] Growth Spread = -87.1% (Analyst -97.2% - Implied -10.2%)
External Resources
Dataroma Stockcircle